Person · CIK 1789545

Richard William Scalzo

Chief Financial Officer at Crescent Biopharma; SVP at Dyne Therapeutics

Earlier: Kaleido Biosciences

Source: Forms 3, 4, 5 and 144 on SEC EDGAR

Sold on Form 4$8.7M

Noticed on Form 144$8.9M

Bought on Form 4$0

Companies3

Holdings now

As reported after the latest Form 3, 4 or 5 at each company.

How these figures work

Options and RSUs are from the latest filing that lists them; earlier grants may also be held. Holdings can be out of date when a person stops filing.

Company	Security	Held	Shares or units	As of
Crescent Biopharma CBIO	Ordinary Shares	Directly	19,730	Sep 16, 2026 · Filing · EDGAR
Crescent Biopharma CBIO	Stock Option (Right to Buy) exercise $13.21, expires Dec 15, 2035, into Ordinary Shares	Directly	57,688	Dec 15, 2025 · Filing · EDGAR
Dyne Therapeutics DYN	Common Stock	Directly	122,330	Mar 11, 2025 · Filing · EDGAR
Dyne Therapeutics DYN	Stock option (right to buy) exercise $29.44, expires Dec 3, 2034, into Common Stock	Directly	52,300	Dec 4, 2024 · Filing · EDGAR
Kaleido Biosciences	Stock Option (Right to Buy) exercise $10.28, expires Aug 15, 2028, into Common Stock	Directly	37,500	Oct 11, 2019 · Filing · EDGAR
Kaleido Biosciences	Stock Option (Right to Buy) exercise $11.78, expires Sep 4, 2028, into Common Stock	Directly	12,500	Oct 11, 2019 · Filing · EDGAR

Sold and noticed by quarter

Sold (Form 4) Noticed (Form 144) Bought (Form 4)

Quarterly totals as a table

Quarter	Sold (Form 4)	Noticed (Form 144)
Q3 2026	$10K	—
Q2 2026	$20K	—
Q2 2025	—	$61K
Q1 2025	$61K	$61K
Q4 2024	$118K	$119K
Q3 2024	$4.3M	$4.5M
Q2 2024	$163K	$163K
Q1 2024	$3.3M	$3.3M
Q4 2023	$74K	$66K
Q3 2023	$27K	—
Q2 2023	$653K	$636K
Q1 2023	$17K	Not machine-readable
Q4 2022	$3K	Not machine-readable
Q1 2022	$3K	Not machine-readable
Q3 2021	$14K	Not machine-readable

Form 144 notices went onto EDGAR as structured data on April 13, 2023. Earlier notices were filed on paper and cannot be read here, so those quarters show no noticed amount.

Planned sales (Form 144) and the sales that followed

Each Form 144 notice of a planned sale, grouped by broker and 10b5-1 plan, with the Form 4 sales we matched to it.

How we match

A Form 144 is a notice of a planned sale by an affiliate. SEC Tracker matches each notice to Form 4 sales by the same person at the same company within 90 days of the notice, up to the shares noticed. The match is our inference, not something either filing states.

Notice date	Noticed	Planned sale	Outcome	Links
Dyne Therapeutics DYN · Stifel Nicolaus & Company · No 10b5-1 plan stated · 16 notices
Jun 11, 2025	1,330 · ~$20K	Jun 11, 2025	Not sold within 90 days	Filing · EDGAR
Jun 5, 2025	914 · ~$12K	Jun 5, 2025	Not sold within 90 days	Filing · EDGAR
May 16, 2025	2,479 · ~$29K	May 16, 2025	Not sold within 90 days	Filing · EDGAR
Mar 11, 2025	1,343 · ~$15K	Mar 11, 2025	Sold as noticed Sold 1,343 at $11.38 on Mar 11 · $15K Form 4	Filing · EDGAR
Mar 5, 2025	915 · ~$11K	Mar 5, 2025	Sold as noticed Sold 917 at $11.83 on Mar 5 · $11K Form 4	Filing · EDGAR
Feb 18, 2025	2,488 · ~$35K	Feb 18, 2025	Sold as noticed Sold 2,488 at $13.95 on Feb 18 · $35K Form 4	Filing · EDGAR
Dec 11, 2024	1,455 · ~$41K	Dec 11, 2024	Sold as noticed Sold 1,455 at $28.12 on Dec 11 · $41K Form 4	Filing · EDGAR
Nov 18, 2024	2,735 · ~$78K	Nov 18, 2024	Sold as noticed Sold 2,735 at $28.20 on Nov 18 · $77K Form 4	Filing · EDGAR
Sep 18, 2024	1,390 · ~$48K	Sep 18, 2024	Sold as noticed Sold 1,390 at $34.55 on Sep 18 · $48K Form 4	Filing · EDGAR
Sep 11, 2024	1,468 · ~$48K	Sep 11, 2024	Sold as noticed Sold 1,468 at $31.89 on Sep 11 · $47K Form 4	Filing · EDGAR
Sep 6, 2024	126,073 · ~$4.2M	Aug 19, 2024	Sold as noticed Sold 126,074 in 2 sales, Sep 6 to Sep 6 · $4.1M likely match Form 4	Filing · EDGAR
Aug 19, 2024	2,752 · ~$124K	Aug 19, 2024	Sold as noticed Sold 2,752 in 2 sales, Aug 19 to Aug 19 · $124K Form 4	Filing · EDGAR
Jun 11, 2024	1,331 · ~$42K	Jun 11, 2024	Sold as noticed Sold 1,331 at $31.34 on Jun 11 · $42K Form 4	Filing · EDGAR
May 16, 2024	2,589 · ~$73K	May 16, 2024	Partly sold Sold 2,126 at $28.20 on May 16 · $60K likely match Form 4	Filing · EDGAR
Mar 11, 2024	2,672 · ~$68K	Mar 11, 2024	Partly sold Sold 2,052 in 2 sales, Mar 11 to May 16 · $53K likely match Form 4 (1) · Form 4 (2)	Filing · EDGAR
Mar 8, 2024	86,252 · ~$2.3M	Mar 8, 2024	Sold as noticed Sold 87,045 in 3 sales, Mar 8 to Mar 11 · $2.3M Form 4	Filing · EDGAR
Dyne Therapeutics DYN · Stifel Nicolaus & Company · 10b5-1 plan adopted Jul 11, 2023 · 1 notice
Jun 10, 2024	1,590 · ~$48K	Jun 10, 2024	Sold as noticed Sold 1,590 at $30.23 on Jun 10 · $48K Form 4	Filing · EDGAR
Dyne Therapeutics DYN · E*Trade Financial · No 10b5-1 plan stated · 4 notices
Mar 7, 2024	2,273 · ~$59K	Mar 7, 2024	Sold as noticed Sold 2,273 at $25.85 on Mar 7 · $59K Form 4	Filing · EDGAR
Dec 11, 2023	1,380 · ~$15K	Dec 11, 2023	Sold as noticed Sold 1,380 at $10.72 on Dec 11 · $15K Form 4	Filing · EDGAR
Jun 15, 2023	10,000 · ~$120K	Jun 15, 2023	Partly sold Sold 1,397 at $10.41 on Sep 12 · $15K likely match Form 4	Filing · EDGAR
Jun 13, 2023	40,000 · ~$515K	Jun 13, 2023	Partly sold Sold 11,390 in 2 sales, Jun 13 to Jun 15 · $138K likely match Form 4	Filing · EDGAR
Dyne Therapeutics DYN · Stifel Financial · 10b5-1 plan adopted Jul 11, 2023 · 6 notices
Mar 1, 2024	9,311 · ~$263K	Mar 1, 2024	Partly sold Sold 9,036 in 2 sales, Mar 1 to Mar 8 · $255K likely match Form 4 (1) · Form 4 (2)	Filing · EDGAR
Feb 29, 2024	3,429 · ~$94K	Feb 29, 2024	Sold as noticed Sold 3,429 at $27.50 on Feb 29 · $94K Form 4	Filing · EDGAR
Jan 26, 2024	13,000 · ~$316K	Jan 26, 2024	Sold as noticed Sold 13,000 at $24.34 on Jan 26 · $316K Form 4	Filing · EDGAR
Jan 3, 2024	13,000 · ~$245K	Jan 3, 2024	Sold as noticed Sold 13,000 at $18.81 on Jan 3 · $245K Form 4	Filing · EDGAR
Dec 14, 2023	2,376 · ~$29K	Dec 14, 2023	Sold as noticed Sold 2,376 at $12.02 on Dec 14 · $29K Form 4	Filing · EDGAR
Dec 6, 2023	1,872 · ~$22K	Dec 6, 2023	Partly sold Sold 1,245 in 2 sales, Dec 4 to Mar 1 · $24K likely match Form 4 (1) · Form 4 (2)	Filing · EDGAR
Sales without a matching Form 144 · 10 sales No matching Form 144 found. Not every sale needs one: small sales and sales by people who are not affiliates are exempt.
—	—	—	Sold without notice Crescent Biopharma (CBIO): Sold 568 at $17.90 on Sep 16, 2026 · $10K (10b5-1 plan)	Filing · EDGAR
—	—	—	Sold without notice Crescent Biopharma (CBIO): Sold 1,112 at $17.99 on Jun 22, 2026 · $20K (10b5-1 plan)	Filing · EDGAR
—	—	—	Sold without notice Dyne Therapeutics (DYN): Sold 1,872 at $12.01 on Dec 6, 2023 · $22K (10b5-1 plan)	Filing · EDGAR
—	—	—	Sold without notice Dyne Therapeutics (DYN): Sold 1,290 at $9.41 on Sep 18, 2023 · $12K (10b5-1 plan)	Filing · EDGAR
—	—	—	Sold without notice Dyne Therapeutics (DYN): Sold 40,000 at $12.89 on Jun 13, 2023 · $516K	Filing · EDGAR
—	—	—	Notice not machine-readable Dyne Therapeutics (DYN): Sold 1,311 at $13.33 on Mar 14, 2023 · $17K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Dyne Therapeutics (DYN): Sold 312 at $10.87 on Dec 12, 2022 · $3K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Dyne Therapeutics (DYN): Sold 308 at $8.73 on Mar 11, 2022 · $3K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Dyne Therapeutics (DYN): Sold 492 at $16.11 on Sep 21, 2021 · $8K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Dyne Therapeutics (DYN): Sold 367 at $15.61 on Sep 20, 2021 · $6K (10b5-1 plan)	Filing · EDGAR

Every transaction, by company

Each Form 3, 4 and 5 transaction in plain words, newest first.

How these figures work

Values are shares times the price each filing states; grants, exercises and gifts usually state no price. Held after is what the filing reports was held once the transaction was done, directly or through the named holder.

Crescent Biopharma CBIO Chief Financial Officer · filings 2025 to 2026 · sold $30K

Date	Transaction	Shares	Price	Value	Held after	Source
Sep 16, 2026	Sale under a 10b5-1 plan	−568	$17.90	$10K	19,730 direct	Filing · EDGAR
Jun 22, 2026	Sale under a 10b5-1 plan	−1,112	$17.99	$20K	20,298 direct	Filing · EDGAR
Dec 15, 2025	Grant or award from the company	+14,422			14,422 direct	Filing · EDGAR
Dec 15, 2025	Grant or award from the company	+5,000			19,422 direct	Filing · EDGAR
Dec 15, 2025	Grant or award from the company Stock Option (Right to Buy)	+57,688			57,688 direct	Filing · EDGAR

Dyne Therapeutics DYN SVP, Head of Finance & Admin. · filings 2020 to 2025 · sold $8.7M · $8.9M noticed on Form 144

Date	Transaction	Shares	Price	Value	Held after	Source
Mar 11, 2025	Sale under a 10b5-1 plan	−1,343	$11.38	$15K	122,330 direct	Filing · EDGAR
Mar 5, 2025	Sale under a 10b5-1 plan	−917	$11.83	$11K	123,673 direct	Filing · EDGAR
Feb 18, 2025	Sale under a 10b5-1 plan	−2,488	$13.95	$35K	124,590 direct	Filing · EDGAR
Dec 11, 2024	Sale under a 10b5-1 plan	−1,455	$28.12	$41K	127,078 direct	Filing · EDGAR
Dec 4, 2024	Grant or award from the company	+32,700			128,533 direct	Filing · EDGAR
Dec 4, 2024	Grant or award from the company Stock option (right to buy)	+52,300			52,300 direct	Filing · EDGAR
Nov 18, 2024	Sale under a 10b5-1 plan	−2,735	$28.20	$77K	95,833 direct	Filing · EDGAR
Sep 18, 2024	Sale under a 10b5-1 plan	−1,390	$34.55	$48K	98,568 direct	Filing · EDGAR
Sep 11, 2024	Sale under a 10b5-1 plan	−1,468	$31.89	$47K	99,958 direct	Filing · EDGAR
Sep 6, 2024	Option or RSU exercised or converted	+6,502	$5.54	$36K	117,524 direct	Filing · EDGAR
Sep 6, 2024	Option or RSU exercised or converted	+3,353	$5.54	$19K	120,877 direct	Filing · EDGAR
Sep 6, 2024	Option or RSU exercised or converted	+34,833	$19.00	$662K	155,710 direct	Filing · EDGAR
Sep 6, 2024	Option or RSU exercised or converted	+16,696	$13.12	$219K	172,406 direct	Filing · EDGAR
Sep 6, 2024	Option or RSU exercised or converted	+29,792	$8.58	$256K	202,198 direct	Filing · EDGAR
Sep 6, 2024	Option or RSU exercised or converted	+18,750	$10.72	$201K	220,948 direct	Filing · EDGAR
Sep 6, 2024	Option or RSU exercised or converted	+6,552	$10.88	$71K	227,500 direct	Filing · EDGAR
Sep 6, 2024	Open-market or private sale	−124,374	$32.14	$4M	103,126 direct	Filing · EDGAR
Sep 6, 2024	Open-market or private sale	−1,700	$32.63	$55K	101,426 direct	Filing · EDGAR
Sep 6, 2024	Option or RSU exercised or converted Stock option (right to buy)	−6,502			0 direct	Filing · EDGAR
Sep 6, 2024	Option or RSU exercised or converted Stock option (right to buy)	−3,353			0 direct	Filing · EDGAR
Sep 6, 2024	Option or RSU exercised or converted Stock option (right to buy)	−34,833			742 direct	Filing · EDGAR
Sep 6, 2024	Option or RSU exercised or converted Stock option (right to buy)	−16,696			8,348 direct	Filing · EDGAR
Sep 6, 2024	Option or RSU exercised or converted Stock option (right to buy)	−29,792			25,208 direct	Filing · EDGAR
Sep 6, 2024	Option or RSU exercised or converted Stock option (right to buy)	−18,750			26,250 direct	Filing · EDGAR
Sep 6, 2024	Option or RSU exercised or converted Stock option (right to buy)	−6,552			28,394 direct	Filing · EDGAR
Aug 19, 2024	Sale under a 10b5-1 plan	−2,442	$45.01	$110K	111,332 direct	Filing · EDGAR
Aug 19, 2024	Sale under a 10b5-1 plan	−310	$46.00	$14K	111,022 direct	Filing · EDGAR
Jun 11, 2024	Sale under a 10b5-1 plan	−1,331	$31.34	$42K	113,774 direct	Filing · EDGAR
Jun 10, 2024	Sale under a 10b5-1 plan	−1,590	$30.23	$48K	115,105 direct	Filing · EDGAR
May 16, 2024	Sale under a 10b5-1 plan	−2,126	$28.20	$60K	117,157 direct	Filing · EDGAR
May 16, 2024	Sale under a 10b5-1 plan	−462	$28.59	$13K	116,695 direct	Filing · EDGAR
Mar 11, 2024	Sale under a 10b5-1 plan	−1,082	$25.70	$28K	120,873 direct	Filing · EDGAR
Mar 11, 2024	Sale under a 10b5-1 plan	−1,590	$24.99	$40K	119,283 direct	Filing · EDGAR
Mar 8, 2024	Option or RSU exercised or converted	+68,919	$5.54	$382K	190,874 direct	Filing · EDGAR
Mar 8, 2024	Option or RSU exercised or converted	+17,333	$5.54	$96K	208,207 direct	Filing · EDGAR
Mar 8, 2024	Sale under a 10b5-1 plan	−30,755	$25.31	$778K	177,452 direct	Filing · EDGAR
Mar 8, 2024	Sale under a 10b5-1 plan	−55,208	$26.72	$1.5M	122,244 direct	Filing · EDGAR
Mar 8, 2024	Sale under a 10b5-1 plan	−289	$27.33	$8K	121,955 direct	Filing · EDGAR
Mar 8, 2024	Option or RSU exercised or converted Stock option (right to buy)	−68,919			9,855 direct	Filing · EDGAR
Mar 8, 2024	Option or RSU exercised or converted Stock option (right to buy)	−17,333			0 direct	Filing · EDGAR
Mar 7, 2024	Sale under a 10b5-1 plan	−2,273	$25.85	$59K	121,955 direct	Filing · EDGAR
Mar 1, 2024	Option or RSU exercised or converted	+9,311	$1.03	$10K	133,539 direct	Filing · EDGAR
Mar 1, 2024	Sale under a 10b5-1 plan	−8,747	$28.22	$247K	124,792 direct	Filing · EDGAR
Mar 1, 2024	Sale under a 10b5-1 plan	−564	$28.65	$16K	124,228 direct	Filing · EDGAR
Mar 1, 2024	Option or RSU exercised or converted Stock option (right to buy)	−9,311			0 direct	Filing · EDGAR
Feb 29, 2024	Option or RSU exercised or converted	+3,429	$1.03	$4K	127,657 direct	Filing · EDGAR
Feb 29, 2024	Sale under a 10b5-1 plan	−3,429	$27.50	$94K	124,228 direct	Filing · EDGAR
Feb 29, 2024	Option or RSU exercised or converted Stock option (right to buy)	−3,429			9,311 direct	Filing · EDGAR
Jan 26, 2024	Option or RSU exercised or converted	+13,000	$1.03	$13K	137,228 direct	Filing · EDGAR
Jan 26, 2024	Sale under a 10b5-1 plan	−13,000	$24.34	$316K	124,228 direct	Filing · EDGAR
Jan 26, 2024	Option or RSU exercised or converted Stock option (right to buy)	−13,000			12,740 direct	Filing · EDGAR
Jan 3, 2024	Option or RSU exercised or converted	+13,000	$1.03	$13K	137,228 direct	Filing · EDGAR
Jan 3, 2024	Sale under a 10b5-1 plan	−13,000	$18.81	$245K	124,228 direct	Filing · EDGAR
Jan 3, 2024	Option or RSU exercised or converted Stock option (right to buy)	−13,000			25,740 direct	Filing · EDGAR
Dec 14, 2023	Sale under a 10b5-1 plan	−2,376	$12.02	$29K	124,228 direct	Filing · EDGAR
Dec 11, 2023	Sale under a 10b5-1 plan	−1,380	$10.72	$15K	126,604 direct	Filing · EDGAR
Dec 6, 2023	Sale under a 10b5-1 plan	−1,872	$12.01	$22K	127,984 direct	Filing · EDGAR
Dec 4, 2023	Sale under a 10b5-1 plan	−681	$12.01	$8K	129,856 direct	Filing · EDGAR
Nov 15, 2023	Grant or award from the company	+89,742			130,537 direct	Filing · EDGAR
Nov 15, 2023	Grant or award from the company Stock Option (right to buy)	+34,946			34,946 direct	Filing · EDGAR

23 earlier transactions are in the filing list below.

Kaleido Biosciences Principal Accounting Officer · filings 2019 to 2019

No transactions in the filings read; Form 144 notices are listed above.

All 68 Forms 3, 4, 5 and 144

Filed	Form	Company	Links
Sep 18, 2026	Form 4	Crescent Biopharma CBIO	Filing · EDGAR
Jun 23, 2026	Form 4	Crescent Biopharma CBIO	Filing · EDGAR
Dec 17, 2025	Form 4	Crescent Biopharma CBIO	Filing · EDGAR
Jun 23, 2025	Form 3	Crescent Biopharma CBIO	Filing · EDGAR
Jun 11, 2025	Form 144	Dyne Therapeutics DYN	Filing · EDGAR
Jun 5, 2025	Form 144	Dyne Therapeutics DYN	Filing · EDGAR
May 16, 2025	Form 144	Dyne Therapeutics DYN	Filing · EDGAR
Mar 13, 2025	Form 4	Dyne Therapeutics DYN	Filing · EDGAR
Mar 11, 2025	Form 144	Dyne Therapeutics DYN	Filing · EDGAR
Mar 7, 2025	Form 4	Dyne Therapeutics DYN	Filing · EDGAR
Mar 5, 2025	Form 144	Dyne Therapeutics DYN	Filing · EDGAR
Feb 18, 2025	Form 144	Dyne Therapeutics DYN	Filing · EDGAR
Feb 18, 2025	Form 4	Dyne Therapeutics DYN	Filing · EDGAR
Dec 11, 2024	Form 144	Dyne Therapeutics DYN	Filing · EDGAR
Dec 11, 2024	Form 4	Dyne Therapeutics DYN	Filing · EDGAR
Dec 6, 2024	Form 4	Dyne Therapeutics DYN	Filing · EDGAR
Nov 18, 2024	Form 144	Dyne Therapeutics DYN	Filing · EDGAR
Nov 18, 2024	Form 4	Dyne Therapeutics DYN	Filing · EDGAR
Sep 19, 2024	Form 4	Dyne Therapeutics DYN	Filing · EDGAR
Sep 18, 2024	Form 144	Dyne Therapeutics DYN	Filing · EDGAR
Sep 11, 2024	Form 144	Dyne Therapeutics DYN	Filing · EDGAR
Sep 11, 2024	Form 4	Dyne Therapeutics DYN	Filing · EDGAR
Sep 10, 2024	Form 4	Dyne Therapeutics DYN	Filing · EDGAR
Sep 6, 2024	Form 144	Dyne Therapeutics DYN	Filing · EDGAR
Aug 20, 2024	Form 4	Dyne Therapeutics DYN	Filing · EDGAR
Aug 19, 2024	Form 144	Dyne Therapeutics DYN	Filing · EDGAR
Jun 11, 2024	Form 144	Dyne Therapeutics DYN	Filing · EDGAR
Jun 11, 2024	Form 4	Dyne Therapeutics DYN	Filing · EDGAR
Jun 10, 2024	Form 144	Dyne Therapeutics DYN	Filing · EDGAR
May 17, 2024	Form 4	Dyne Therapeutics DYN	Filing · EDGAR
May 16, 2024	Form 144	Dyne Therapeutics DYN	Filing · EDGAR
Mar 12, 2024	Form 4	Dyne Therapeutics DYN	Filing · EDGAR
Mar 11, 2024	Form 144	Dyne Therapeutics DYN	Filing · EDGAR
Mar 11, 2024	Form 4	Dyne Therapeutics DYN	Filing · EDGAR
Mar 8, 2024	Form 144	Dyne Therapeutics DYN	Filing · EDGAR
Mar 7, 2024	Form 144	Dyne Therapeutics DYN	Filing · EDGAR
Mar 1, 2024	Form 4	Dyne Therapeutics DYN	Filing · EDGAR
Mar 1, 2024	Form 144	Dyne Therapeutics DYN	Filing · EDGAR
Feb 29, 2024	Form 144	Dyne Therapeutics DYN	Filing · EDGAR
Jan 26, 2024	Form 4	Dyne Therapeutics DYN	Filing · EDGAR
Jan 26, 2024	Form 144	Dyne Therapeutics DYN	Filing · EDGAR
Jan 4, 2024	Form 4	Dyne Therapeutics DYN	Filing · EDGAR
Jan 3, 2024	Form 144	Dyne Therapeutics DYN	Filing · EDGAR
Dec 14, 2023	Form 4	Dyne Therapeutics DYN	Filing · EDGAR
Dec 14, 2023	Form 144	Dyne Therapeutics DYN	Filing · EDGAR
Dec 12, 2023	Form 4	Dyne Therapeutics DYN	Filing · EDGAR
Dec 11, 2023	Form 144	Dyne Therapeutics DYN	Filing · EDGAR
Dec 6, 2023	Form 4	Dyne Therapeutics DYN	Filing · EDGAR
Dec 6, 2023	Form 144	Dyne Therapeutics DYN	Filing · EDGAR
Nov 16, 2023	Form 4	Dyne Therapeutics DYN	Filing · EDGAR
Sep 20, 2023	Form 4	Dyne Therapeutics DYN	Filing · EDGAR
Sep 13, 2023	Form 4	Dyne Therapeutics DYN	Filing · EDGAR
Jun 15, 2023	Form 4	Dyne Therapeutics DYN	Filing · EDGAR
Jun 15, 2023	Form 144	Dyne Therapeutics DYN	Filing · EDGAR
Jun 13, 2023	Form 144	Dyne Therapeutics DYN	Filing · EDGAR
Mar 15, 2023	Form 4	Dyne Therapeutics DYN	Filing · EDGAR
Dec 13, 2022	Form 4	Dyne Therapeutics DYN	Filing · EDGAR
Sep 21, 2022	Form 4	Dyne Therapeutics DYN	Filing · EDGAR
Sep 15, 2022	Form 4	Dyne Therapeutics DYN	Filing · EDGAR
Jul 13, 2022	Form 4	Dyne Therapeutics DYN	Filing · EDGAR
Jul 6, 2022	Form 4	Dyne Therapeutics DYN	Filing · EDGAR
Jun 15, 2022	Form 4	Dyne Therapeutics DYN	Filing · EDGAR
Mar 14, 2022	Form 4	Dyne Therapeutics DYN	Filing · EDGAR
Dec 14, 2021	Form 4	Dyne Therapeutics DYN	Filing · EDGAR
Sep 22, 2021	Form 4	Dyne Therapeutics DYN	Filing · EDGAR
Sep 18, 2020	Form 4	Dyne Therapeutics DYN	Filing · EDGAR
Sep 16, 2020	Form 3	Dyne Therapeutics DYN	Filing · EDGAR
Oct 15, 2019	Form 3	Kaleido Biosciences	Filing · EDGAR

Every figure is as filed with the SEC on Forms 3, 4, 5 and 144. Holdings are the amounts reported after each person's latest filing at each company and can be out of date. Matching a Form 144 notice to Form 4 sales is SEC Tracker's inference from owner, company, dates and share counts, not something the filings state. Not investment advice. Not affiliated with the U.S. SEC.